Status:
TERMINATED
Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)
Lead Sponsor:
AstraZeneca
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to follow the management of blood lipids in patients with planned percutaneous coronary intervention (widening of coronary vessels) in a period from 6 to 10 weeks after the...
Eligibility Criteria
Inclusion
- Male or nonpregnant female
- Coronary patient hospitalised for elective PCI
- Hypercholesterolaemia defined as LDL-C ≥ 2 mmol/L
Exclusion
- Any chronic inflammatory condition
- Chronic anti-inflammatory pharmacotherapy (except low-dose ASA)
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01190072
Start Date
September 1 2010
End Date
March 1 2011
Last Update
January 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Maribor, Slovenia